4//SEC Filing
ZDRAVESKI ZORAN 4
Accession 0000950170-24-101161
CIK 0001783328other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 6:46 PM ET
Size
20.5 KB
Accession
0000950170-24-101161
Insider Transaction Report
Form 4
ZDRAVESKI ZORAN
See Remarks
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-08-23−25,000→ 25,000 totalExercise: $3.27Exp: 2032-07-24→ Voting Common Stock (25,000 underlying) - Exercise/Conversion
Voting Common Stock
2024-08-23$1.81/sh+13,125$23,756→ 105,236 total - Sale
Voting Common Stock
2024-08-23$5.78/sh−164,686$952,116→ 4,716 total - Exercise/Conversion
Voting Common Stock
2024-08-23$4.85/sh+54,895$266,241→ 67,111 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-23−64,166→ 365,834 totalExercise: $2.49Exp: 2033-06-12→ Voting Common Stock (64,166 underlying) - Exercise/Conversion
Voting Common Stock
2024-08-23$3.27/sh+25,000$81,750→ 92,111 total - Exercise/Conversion
Voting Common Stock
2024-08-23$2.49/sh+64,166$159,773→ 169,402 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-23−54,895→ 30,105 totalExercise: $4.85Exp: 2032-01-17→ Voting Common Stock (54,895 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-23−13,125→ 21,875 totalExercise: $1.81Exp: 2033-02-01→ Voting Common Stock (13,125 underlying)
Footnotes (6)
- [F1]Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F3]The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- [F4]The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- [F5]The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- [F6]220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.
Documents
Issuer
TScan Therapeutics, Inc.
CIK 0001783328
Entity typeother
Related Parties
1- filerCIK 0001741285
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 6:46 PM ET
- Size
- 20.5 KB